Again, these patients had Omicron, not Delta or another varian | Alex Berenson

Again, these patients had Omicron, not Delta or another variant. Their average age was only 57. They received advanced medical care. They were not healthy but by the standards of American middle age not particularly unhealthy either. Only about 20 percent were obese, and a similar number diabetic.

The researchers did not include a unvaccinated group in the study, so even a theoretical comparison of jabbed to unjabbed people is impossible. But a 1 percent death rate in this group of people is hardly impressive evidence that the vaccines work to prevent severe disease and death.

The study was a review of medical records and not a randomly controlled clinical trial, so it does not prove that Paxlovid caused the reductions. The patients who received Paxlovid might have been subtly different than those who did not.

But the study supports the findings of Pfizer’s clinical trial of Paxlovid, which showed a similarly sized benefit last year. But Pfizer ran that trial only in unvaccinated people, leading some researchers to question whether the medicine would work as well in the vaccinated. This paper suggests it does. (3/4)